Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO(R) ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain

Intranasal abuse-deterrent claim to be added to ARYMO ER prescribing information label WAYNE, Pa., Dec. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrated specialty pharmaceutical compan... Biopharmaceuticals, FDA Egalet Corp, ARYMO ER, morphine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news